 LAUSANNE, Switzerland--BUSINESS WIRE--ADC Therapeutics SA NYSE: ADCT, a commercial-stage biotechnology company leading the development of novel antibody drug conjugates ADCs to treat hematological malignancies and solid tumors, announced today that updated interim results from the ongoing pivotal Phase 2 clinical trial of camidanlumab tesirine Cami in patients with relapsed or refractory Hodgkin lymphoma were presented in an oral presentation Abstract 075 at the 16th Annual Internatio 